Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 12, Issue 7
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
PDF +
Supplementary
Material
Clinical/translational cancer immunotherapy
Original research
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids
Online download statistics by month:
Online download statistics by month: July 2024 to June 2025
Abstract
Full
Pdf
Jul 2024
691
709
209
Aug 2024
113
114
58
Sep 2024
97
99
57
Oct 2024
98
98
42
Nov 2024
121
122
31
Dec 2024
134
135
40
Jan 2025
87
89
44
Feb 2025
157
157
35
Mar 2025
80
80
179
Apr 2025
100
100
43
May 2025
70
70
42
Jun 2025
67
67
32
Total
1815
1840
812
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF